Clinical Trial Detail

NCT ID NCT01266031
Title Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

mixed oligodendroglioma-astrocytoma

astrocytoma

malignant glioma

glioblastoma multiforme

adult oligodendroglioma

gliosarcoma

Therapies

Bevacizumab + Vorinostat

Bevacizumab

Age Groups: adult

No variant requirements are available.